Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less ... more

• Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Mar 2013 , Pages: 48
  Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Betaseron/Betaferon (Multiple Sclerosis)...

• Tcelna (Multiple Sclerosis) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Mar 2013 , Pages: 60
  Tcelna (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tcelna (Multiple Sclerosis) - Forecast and Market Analysis...

• PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022

  EURO€ 3,839.00USD$ 4,995.00GBP£ 3,230.00AUD$ 4,885.00JPY¥ 493,171.00SEK 32 796,00CHF 4'708.00CAD$ 5,090.00 GlobalData, Mar 2013 , Pages: 156
  PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and...

• PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022

  EURO€ 3,839.00USD$ 4,995.00GBP£ 3,230.00AUD$ 4,885.00JPY¥ 493,171.00SEK 32 796,00CHF 4'708.00CAD$ 5,090.00 GlobalData, Mar 2013 , Pages: 155
  PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and...

• Daclizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Mar 2013 , Pages: 61
  Daclizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Daclizumab (Multiple Sclerosis) - Forecast and Market...

• PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022

  EURO€ 3,839.00USD$ 4,995.00GBP£ 3,230.00AUD$ 4,885.00JPY¥ 493,171.00SEK 32 796,00CHF 4'708.00CAD$ 5,090.00 GlobalData, Mar 2013 , Pages: 154
  PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis - China Drug Forecast and...

• Copaxone (Multiple Sclerosis) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Mar 2013 , Pages: 49
  Copaxone (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Copaxone (Multiple Sclerosis) - Forecast and Market...

• PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022

  EURO€ 3,839.00USD$ 4,995.00GBP£ 3,230.00AUD$ 4,885.00JPY¥ 493,171.00SEK 32 796,00CHF 4'708.00CAD$ 5,090.00 GlobalData, Mar 2013 , Pages: 157
  PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis - France Drug Forecast and...

• NU-100 (Multiple Sclerosis) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Mar 2013 , Pages: 60
  NU-100 (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “NU-100 (Multiple Sclerosis) - Forecast and Market Analysis...

• Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Mar 2013 , Pages: 62
  Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Laquinimod (Multiple Sclerosis) - Forecast and Market...

• PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022

  EURO€ 3,839.00USD$ 4,995.00GBP£ 3,230.00AUD$ 4,885.00JPY¥ 493,171.00SEK 32 796,00CHF 4'708.00CAD$ 5,090.00 GlobalData, Mar 2013 , Pages: 154
  PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis - India Drug Forecast and...

• Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Mar 2013 , Pages: 47
  Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Rebif (Multiple Sclerosis) - Forecast and Market Analysis...

• Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Mar 2013 , Pages: 48
  Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tysabri (Multiple Sclerosis) - Forecast and Market...

• PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022

  EURO€ 3,839.00USD$ 4,995.00GBP£ 3,230.00AUD$ 4,885.00JPY¥ 493,171.00SEK 32 796,00CHF 4'708.00CAD$ 5,090.00 GlobalData, Mar 2013 , Pages: 157
  “PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022” Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by...

• PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and Market Analysis to 2022

  EURO€ 3,839.00USD$ 4,995.00GBP£ 3,230.00AUD$ 4,885.00JPY¥ 493,171.00SEK 32 796,00CHF 4'708.00CAD$ 5,090.00 GlobalData, Mar 2013 , Pages: 153
  “PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and Market Analysis to 2022” Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination,...

• Siponimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Mar 2013 , Pages: 61
  “Siponimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022” Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal...

• Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Mar 2013 , Pages: 63
  Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lemtrada (Multiple Sclerosis) - Forecast and Market...

• Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 37
  Dementia Associated With Alzheimer's Disease – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2013', provides an overview...

• Musculoskeletal Pain - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 166
  Musculoskeletal Pain – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Musculoskeletal Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Fatigue - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 61
  Fatigue – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Fatigue - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 59
  Peripheral Neuropathy (Sensory Neuropathy) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2013', provides an overview...

• Tourette Syndrome - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 57
  Tourette Syndrome – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Tourette Syndrome - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Appetite (Eating) Disorders - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 80
  Appetite (Eating) Disorders – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Appetite (Eating) Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Back Pain - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 97
  Back Pain – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Back Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Brain Hemorrhage - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 32
  Brain Hemorrhage – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Brain Hemorrhage - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Spinal Cord Disorders - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 151
  Spinal Cord Disorders – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Spinal Cord Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Anorexia Nervosa - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 37
  Anorexia Nervosa – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Anorexia Nervosa - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Lewy body Dementia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 28
  Lewy body Dementia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Lewy body Dementia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Schizophrenia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 343
  Schizophrenia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Schizophrenia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GBI Research, Mar 2013 , Pages: 184
  GBI Research, the leading business intelligence provider, has released its latest research “Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease...

• Severe Psoriasis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 54
  Severe Psoriasis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Severe Psoriasis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 98
  Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Cough - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 72
  Cough – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Cough - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 103
  Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2013', provides an overview...

• B-Cell Lymphomas - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 580
  B-Cell Lymphomas – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'B-Cell Lymphomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 284
  Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline...

• Metabolic Disorders - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 195
  Metabolic Disorders – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Metabolic Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Asthma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 279
  Asthma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Asthma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Psoriasis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 527
  Psoriasis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Psoriasis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Dental Pain Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Feb 2013 , Pages: 104
  Dental Pain Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Dental Pain Global Clinical Trials Review, H1, 2013" provides data on the Dental Pain clinical trial scenario....

• Sleep Disorders Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Feb 2013 , Pages: 114
  Sleep Disorders Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Sleep Disorders Global Clinical Trials Review, H1, 2013" provides data on the Sleep Disorders clinical trial...

• Hyperalgesia Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Feb 2013 , Pages: 70
  Hyperalgesia Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario....

• Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 30
  Primary Progressive Multiple Sclerosis (PPMS) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H1 2013', provides an overview...

• Equine Encephalitis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 35
  Equine Encephalitis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Equine Encephalitis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Acute Ischemic Stroke - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 102
  Acute Ischemic Stroke – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Acute Ischemic Stroke - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Parkinson's Disease - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 225
  Parkinson's Disease – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Parkinson's Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Huntington's Disease - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 178
  Huntington's Disease – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Huntington's Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 68
  Spinal Muscular Atrophy (SMA) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Epilepsy - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 195
  Epilepsy – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Epilepsy - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 158
  Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2013', provides an...